Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer

Area of Science:

• Biochemistry
• Oncology
• Molecular Biology

Background:

• Sphingosine kinase 1 (SK1) is a lipid enzyme implicated in cancer progression.
• SK1 converts sphingosine to sphingosine-1-phosphate, promoting cell proliferation, migration, and inhibiting apoptosis.
• Elevated SK1 expression correlates with poor prognosis in various cancers, including prostate cancer.

Purpose of the Study:

• To review the role of SK1 in cancer progression.
• To highlight the therapeutic potential of SK1-targeting agents in combination with existing cancer treatments.
• To discuss the recent emergence of SK1 inhibitors for clinical application.

Main Methods:

• Literature review of studies on SK1 function and therapeutic targeting.
• Analysis of evidence from preclinical cancer models (cell lines and animal models).
• Examination of the impact of SK1 inhibition on cancer hallmarks and treatment response.

Main Results:

• SK1 activation drives oncogenic transformation, tumor growth, therapy resistance, neovascularization, and metastasis.
• SK1-targeting therapies demonstrate synergistic effects with docetaxel chemotherapy and radiotherapy in prostate cancer models.
• The development of clinically applicable SK1 inhibitors is a recent advancement.

Conclusions:

• SK1 is a critical mediator of cancer progression and a viable therapeutic target.
• Combination therapies involving SK1 inhibitors hold significant potential for improving cancer treatment outcomes.
• The availability of SK1 inhibitors is expected to accelerate clinical trials and patient treatment.